NCT Number: NCT06819787
Hormonal contraceptives are medications that require a prescription, traditionally from a physician or advanced practice provider. Over the past decade, pharmacists have gained the authority to prescribe contraceptives in many states, allowing patients to access these medications directly in pharmacies without first seeing another healthcare provider. The Pharmacist Resource to Implement Services as Modules (PRISM) is an Electronic Health Record platform designed to streamline workflows and provide clinical decision support, making it easier and safer to deliver clinical services in community pharmacies. This pilot study will evaluate patient-reported outcomes for women receiving contraceptive services from pharmacists using the PRISM platform at five community pharmacies across the United States over a 12-week period. The study will assess the quality of care, contraception continuation and failure rates, side effect rates, preventative healthcare utilization, and overall patient experience with pharmacy contraceptive services.
Looking for future studies?
Notify Me18 year–51 year
Female
Interventional
Not applicable
Calabasas Pharmacy, Calabasas, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An electronic health record (EHR) platform specifically designed to support community pharmacists in delivering contraceptive services. The platform streamlines clinical workflows, provides clinical decision support, and promotes adherence to the US Medical Eligibility Criteria (USMEC) guidelines and state regulatory requirements.
Time frame: Within 7 days post-intervention
The percentage of patients who report that the pharmacist provided overall patient-centered care, as defined by achieving the highest rating on all four items of the PCCC survey.
Time frame: Within 97 days post-intervention
The percentage of patients who report continuous use of their selected contraceptive method three months after the pharmacist encounter. Continuous use is defined as using the method at the time of the survey with no gaps in use of one month or longer.
Time frame: Within 97 days post-intervention
The percentage of patients who have experienced unintended pregnancy while using the contraceptive method prescribed during the encounter.
Time frame: Within 97 days post-intervention
The percentage of patients who report one or more side effects from the contraceptive method prescribed during the encounter.
Time frame: Within 97 days post-intervention
7-point Likert scale rating of patient satisfaction with the contraceptive method prescribed during the encounter.
Time frame: Within 97 days post-intervention
A series of Likert scale, Yes/No, and open-ended questions to discover patient perceptions, attitudes, and satisfaction regarding pharmacist contraceptive services.
Time frame: Within 97 post-intervention
A series of Yes/No and multiple-choice questions to discover patient utilization of preventative health services including primary care and medical screening exams.
OvaryIt, LLC
Industry
Patient-Reported Outcomes of Contraceptive Services Rendered by Community Pharmacists Using the Pharmacist Resource to Implement Services as Modules Platform: The PRISM-CS Study
Acronym: PRISM-CS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06557499
Contraception
Berkeley, California, United States
View Trial DetailsNCT07326007
Contraception
Giza, Egypt
View Trial DetailsNCT05732142
Contraception, Gender Equity
La Jolla, California, United States
View Trial DetailsNCT03127722
Contraception
Chandler, Arizona, United States
View Trial Details